Proefschrift

Basanta, D. and Anderson, A. (2018). Homeostasis back and forth: An ecoevolutionary perspective of cancer. Cold Spring Harbor Perspectives in Medicine , 7(9):a028332. 27 Basanta, D., Gatenby, R., and Anderson, A. (2012a). Exploiting evolution to treat drug resistance: combination therapy and the double bind. Molecular Pharmaceutics , 9(4):914– 921. 27 Basanta, D., Scott, J., Fishman, M., Ayala, G., Hayward, S., and Anderson, A. (2012b). Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game. British Journal of Cancer , 106(1):174–181. 27, 59, 98 Bayer, P., Brown, J., and Stanˇkova´, K. (2018). A two-phenotype model of immune evasion by cancer cells. Journal of Theoretical Biology , 455:191–204. 27, 97 Begg, C. and Carbone, P. (1983). Clinical trials and drug toxicity in the elderly. the experience of the Eastern Cooperative Oncology Group. Cancer , 52(11):1986–1992. 7 Beier, J., Keating, J., Githure, J., Macdonald, M., Impoinvil, D., and Novak, R. (2008). Integrated vector management for malaria control. Malaria Journal , 7(1):1–10. 24 Bekaii-Saab, T., Ou, F.-S., Anderson, D., Ahn, D., Boland, P., Ciombor, K., Jacobs, N., Desnoyers, R., Cleary, J., Meyers, J., et al. (2018). Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) - an ACCRU network study. Journal of Clinical Oncology , 36(4 suppl):611. 97 Bellman, R. (1957). Dynamic Programming . Princeton University Press, Princeton, New Jersey. 76 Benzekry, S. and Hahnfeldt, P. (2013). Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. Journal of Theoretical Biology , 335:235– 244. 14, 64 Bidard, F., Fehm, T., Ignatiadis, M., Smerage, J., Alix-Panabi`eres, C., Janni, W., Messina, C., Paoletti, C., Mu¨ller, V., Hayes, D., et al. (2013). Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer and Metastasis Reviews , 32(1-2):179–188. 59 Blumenthal, G., Birnkrant, D., and Pazdur, R. (2018). Leveraging the success of HIV drug development paradigms for cancer. Clinical Cancer Research , 24(11):2491–2492. 23 Bouche, G., Andr´e, N., Banavali, S., Berthold, F., Berruti, A., Bocci, G., Brandi, G., Cavallaro, U., Cinieri, S., Colleoni, M., Curigliano, G., Di Desidero, T., Eniu, A., Fazio, N., Kerbel, R., Hutchinson, L., Ledzewicz, U., Munzone, E., Pasquier, E., Scharovsky, O., Shaked, Y., Stˇerba, J., Villalba, M., and Bertolini, F. (2014). Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. ecancermedicalscience , 8:463–481. 75 167